Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer
Conditions: Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-small Cell Lung Cancer Interventions: Device: ViewRay MR-Linear Accelerator; Radiation: Radiation therapy; Drug: Paclitaxel; Drug: Carboplatin AUC; Biological: Durvalumab Sponsor: Washington University School of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Radiation Therapy | Research